Kaposi s Sarcoma. Akifumi IMAMURA. Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital AIDS

Transcription

1 **3 The Japanese Society for AIDS Research The Journal of AIDS Research :Human herpesvirus 2 HHV-2 Kaposi s Sarcoma Akifumi IMAMURA Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Moriz Kaposi * +32+ AIDS AIDS AIDS - +* * HIV Highly active antiretroviral therapy : mm cm AIDS AIDS Clinical Trials Group : ACTG. Tu- mor : T CD. Immune + +33* **2 system : I 3. Systemic illness : S * / / Tumor : T : **3 +*

2 A Imamura : Kaposi s Sarcoma HIV HIV / 0 +*.0 partial response : PR AIDS * **2 ABV doxorubicin bleomycinvincristine BV bleomycinvincristine -2.* + ABV / 22 Response Rate : RR HIV / / 23 Dupont -3. complete response : CR. Tumor : T CD. ** / ml CD. ** / ml Immune system : I Systemic illness : S B B performance status1* performance status1* Karnofsky Karnofsky HIV +2* +*

3 The Journal of AIDS Research Vol. ++ No. - **3 +- * mgm doxorubicin A * mgm bleomycin B doxorubicin polyethylene- +* mgm vincristine V + mg 0 glycol doxorubicin +/./ ABV / QOL AIDS +0 /2 ABV * mgm - ABV -. - vs ABV n+-- ABV n+/ No. No. P CR CCR PR 0*./ *4**+ * SD 1* / PD +4/ +* 24* * * * * + *42 * * -3 /* *4*+.** 3* 3 * *4/3 * Fisher ** Log-rank +/. vs ABV : Grade- n+-- ABV n+/ No. No. P.2-0 /. NS * +/. -. *4** *4** *4** / 0 / *4* NS. - 1 /40 NS +/

4 A Imamura : Kaposi s Sarcoma QOL AIDS 1* 2* +1 oa +2 HHV-2 + CD. AIDS

5 The Journal of AIDS Research Vol. ++ No. - **3 +* antiretroviral therapy. J Clin Oncol - : +/- +0* **/. Martin-Carbonero L Barrios A Saballs P et al. : Pegylated QOL liposomal doxorubicin plus highly active antiretro- viral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi s sarcoma. AIDS +2 : * **.. ++ Kirova YM Belembaogo E Frikha H et al. : Radiotherapy in the management of epidemic Kaposi s sarcoma : A retrospective study of 0.- cases. Radiother Oncol.0 : Hernandez DE Perez JR : Advanced epidemic Kaposi s + Kaposi M : Idiopathic multiple pigmented sarcoma of sarcoma : treatment with bleomycin or combination of the skin. CA Cancer J Clin - : doxorubicin bleomycin and vincristine. Int J Dermatol Hymes KB et al. : Kaposi s sarcoma in homosexual men : -/ : a report of eight cases Lancet /320** Gill PS Rarick M McCutchan JA et al. : Systemic treatment - Jones JL : Surveillance for AIDS-Defining Opportunistic Illnesses MMWR.2 (SS-) : of AIDS-related Kaposi s sarcoma. Results of a ran- domized trial. Am J Med +3 : Krown SE Metroka C Wernz JC : Kaposi s sarcoma in +. : Doxil Pegylated Liposomal Doxthe acquired immune deficiency syndrome : a proposal orubicin -/ 2 : **2. for uniform evaluation response and staging criteria. +/ Northfelt DW et al. : Pegylated liposomal doxorubicin AIDS Clinical Trials Group Oncology Committee. J Clin versus doxorubicin bleomycin and vincristine in the treat- Oncol 1 ( 3 ) : +*+ +* ment of AIDS-related Kaposi s sarcoma : Results of ran- / Palella FJ et al. : Declining morbidity and mortality domized phase III clinical trial. J Clin Oncol +0../ among patients woth advanced human immunodeficiency./ virus infection. N Eng J Med --2 : 2/-20* Osoba D Northfelt DW Budd DW et al. : E# ect of treatnodeficiency 0 Jacobson LP Yamashita TE Detels R et al. : Impact of ment on health-related quality of life in acquired immupotent antiretroviral therapy on the incidence of Kaposi s syndrome (AIDS)-related Kaposi s sarcoma : sarcoma and non-hodgkin s lymphomas among HIV-+ - a randomized trial of pegylated-liposomal doxorubicin infected individuals. Multicenter AIDS Cohort Study. versus doxorubicin bleomycin and vincristine. Cancer J Acquire Immune Defic Syndr + (suppl + ) : S-. S.+ Invest +3 : /1- /2* ** Cattelan AM Calabro ML De Rossi A et al. : Long- 1 Dupont C Vasseur E Beauchet A et al. : Long-term ef- term clinical outcome of AIDS-related Kaposi s sarcoma ficacy on Kaposi s sarcoma of highly active antiretrovial during highly active antiretroviral therapy. Int J Oncol therapy in a cohort of HIV-positive patients. AIDS +. : 1 : 11312/ **/ ***. +2 Sheperd FA Beaulieu R Gelmon K et al. : Prospective 2 Nasti G Martellotta F Berretta M et al. : Impact of randomized trial of two dose levels of interferon alfa highly active antiretroviral therapy on the presenting fea- with zidovudine for the therapy of Kaposi s sarcoma astures and outcome of patients with acquired immunode- sociated with human immunodeficiency virus infection : ficiency syndrome-related Kaposi sarcoma. Cancer 32 : A Canadian HIV Clinical Trials Network Study. J Clin..*..0 **-. Oncol +0 : Gallafent JH Buskin SE De Turk PB et al. : Profile of +3 : -* / : 0-. patients with Kaposi s sarcoma in the era of highly active 0-3 **